Nicotinamide mononucleotide (NMN) supplementation promotes neurovascular rejuvenation in aged mice: transcriptional footprint of SIRT1 activation, mitochondrial protection, anti-inflammatory, and anti-apoptotic effects
Mesfin A, Buchowski JM, Zebala LP, Bakhsh WR, Aronson AB, Fogelson JL, et al
AOD 9604 vs Tirzepatide: Summarizing Key Differences Fat Loss Mechanism AOD 9604: Direct lipolysis stimulation and lipogenesis inhibition Tirzepatide: Caloric deficit from appetite suppression plus metabolic optimization Appetite Impact AOD 9604: No significant effect Tirzepatide: Powerful suppression via GLP-1/GIP pathways Metabolic Pathway AOD 9604: Beta-3 adrenergic receptor activation (and likely additional pathways) in adipose tissue Tirzepatide: GLP-1 and GIP receptor agonism affecting glucose metabolism and insulin secretion Evidence Base AOD 9604: Primarily animal studies with mechanistic data Tirzepatide: Extensive human clinical trials with proven outcomes Timeline AOD 9604: 4-6+ weeks for visible effects in animal models Tirzepatide: Progressive weight loss documented across clinical trial periods over as long as 72 weeks How to Choose Between AOD 9604 and Tirzepatide Stop looking for the best peptide and start asking which mechanism addresses YOUR specific physiology
Experts worry the drugs are being used as a tool to restrict eating or control weight in ways that can make eating disorders worse
Growth hormone fragments and fat metabolism
Zur Gewichtsreduktion stehen heute verschiedene Medikamente zur Verfgung, die auf dem GLP-1-Signalweg basieren
